Idiopathic pulmonary hypertension was first described by Argentine therapists in 1901.

In the years 1967-1970, a significant increase in the incidence of pulmonary arterial hypertension was recorded in Europe, attributed to the widespread use of drugs for treating obesity and weight loss. This was associated with the widespread prescription of the anorectic drug aminorex fumarate, which chemically resembled ephedrine. During that time, Europe experienced a genuine boom in the fight against obesity and excess weight, leading to a surge in pulmonary hypertension cases.

A similar situation occurred in Spain in 1981 when an epidemic of toxic complications, clinically manifested as muscle damage, emerged with the consumption of rapeseed oil. Pulmonary hypertension was identified in 2.5% of 20,000 affected individuals. Later, it was proven that the development of this condition was linked to tryptophan present in rapeseed oil.